NCT02555189 2026-04-22
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT04541017 2025-10-16
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT05756166 2025-06-24
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT00775268 2021-03-11
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00686842 2018-06-06
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 1/2 Terminated
NCT00233948 2015-04-01
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
City of Hope Medical Center
Phase 1/2 Terminated